Biohit Oyj - Changes board/management/auditors

Changes in the diagnostics business of Biohit

Biohit Oyj has decided to withdraw from its plans to spin off the diagnostics
business until further notice. The company seeks to increase operational
efficiency by merging the management of diagnostics and liquid handling sales
and marketing. 

In the future, Jukka-Pekka Haapalahti, MSc (biochem), who was appointed
Director of Liquid Handling Sales and Marketing in May 2010, will be
responsible for both areas. Mr Haapalahti has vast experience also from the
diagnostics field; prior to joining Biohit he worked for Roche Diagnostics GmbH
in sales and marketing senior management positions. 

Yrjö E K Wichmann, who has been heading the diagnostics business of Biohit,
will leave his current position on 31 December 2010 by mutual agreement with
the Board and the CEO. 

Jussi Heiniö
President and CEO
Biohit Oyj



Further information:

Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com

Distribution:

NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com



About Biohit Oyj:

Biohit Oyj is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. The company follows a goal-directed and long-term innovation
and patenting strategy. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. 

Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips
as well as pipette maintenance and calibration services for research
institutions, healthcare and industrial laboratories. 

The diagnostics business comprises products and analysis systems for the early
diagnosis and prevention of gastrointestinal diseases, such as the blood-sample
based GastroPanel examinations for the diagnosis of stomach illnesses and
associated risks, quick tests for the diagnosis of lactose intolerance and H.
pylori infection in connection with gastroscopy, and the ColonView examination
for the early detection of intestinal bleeding that indicates a risk of
colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in
an anacidic stomach. 

The Biohit Group employs around 400 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA. The company also has a representative office
in Singapore. Biohit's products are also sold through about 200 distributors in
70 countries. 

Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in
the Small cap/Healthcare group and is traded under the code BIOBV. 

Read more at www.biohit.com